(Q35213465)

7 August 2017

1 reference

title

Clinical pharmacokinetics of oxcarbazepine (English)

1 reference

7 August 2017

1 reference

Theodor W May

1

1 reference

7 August 2017

Elisabeth Korn-Merker

series ordinal

2

1 reference

7 August 2017

Bernhard Rambeck

series ordinal

3

1 reference

7 August 2017

1 January 2003

1 reference

Clinical Pharmacokinetics

7 August 2017

1 reference

7 August 2017

42

1 reference

7 August 2017

12

1 reference

7 August 2017

1023-1042

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-200342120-00002

7 August 2017

0 references

cites work

First dose and steady-state pharmacokinetics of oxcarbazepine and its 10-hydroxy metabolite

1 reference

12 December 2020

Gas chromatographic assay for oxcarbazepine and its main metabolites in plasma

1 reference

12 December 2020

Valproic acid-induced carbamazepine-10,11-epoxide toxicity in children and adolescents

1 reference

12 December 2020

Oxcarbazepine: preclinical anticonvulsant profile and putative mechanisms of action.

1 reference

12 December 2020

Transplacental passage of oxcarbazepine and its metabolites in vivo

1 reference

12 December 2020

Pharmacokinetics of oxcarbazepine and 10-hydroxy-carbazepine in the newborn child of an oxcarbazepine-treated mother

1 reference

12 December 2020

Plasma concentration of topiramate correlates with cerebrospinal fluid concentration

1 reference

12 December 2020

Possible interaction between oxcarbazepine and an oral contraceptive

1 reference

12 December 2020

Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine

1 reference

12 December 2020

Oxcarbazepine does not affect the anticoagulant activity of warfarin

1 reference

12 December 2020

Determination of oxcarbazepine in human plasma by high-performance liquid chromatography

1 reference

12 December 2020

The metabolism of 14C-oxcarbazepine in man

1 reference

12 December 2020

Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication

1 reference

12 December 2020

Rapid micromethod for simultaneous measurement of oxcarbazepine and its active metabolite in plasma by high-performance liquid chromatography

1 reference

12 December 2020

Clinical recommendations for oxcarbazepine

1 reference

12 December 2020

Simple and rapid micro-analytical high-performance liquid chromatographic technique for the assay of oxcarbazepine and its primary active metabolite 10-hydroxycarbazepine

1 reference

12 December 2020

Clinical pharmacology and pharmacokinetics of oxcarbazepine

1 reference

12 December 2020

The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites

1 reference

12 December 2020

Possible oxcarbazepine interaction with cyclosporine serum levels: a single case study

1 reference

12 December 2020

1 reference

12 December 2020

Anticonvulsants and breast feeding: a critical review

1 reference

12 December 2020

Oxcarbazepine disposition: preliminary observations in patients

1 reference

12 December 2020

Pharmacokinetic properties of current antiepileptic drugs: what improvements are needed?

1 reference

12 December 2020

Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication

1 reference

12 December 2020

The distribution of 10-hydroxy carbazepine in blood compartments

1 reference

12 December 2020

Oxcarbazepine: pharmacokinetic interactions and their clinical relevance

1 reference

12 December 2020

Oxcarbazepine: preliminary clinical and pharmacokinetic studies on a new anticonvulsant

1 reference

12 December 2020

The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid

1 reference

12 December 2020

Oxcarbazepine does not interact with cimetidine in healthy volunteers

1 reference

12 December 2020

Fluctuations of 10-hydroxy-carbazepine during the day in epileptic patients

1 reference

12 December 2020

Plasma level monitoring of oxcarbazepine in epileptic patients

1 reference

12 December 2020

Liver enzyme induction and serum lipid levels after replacement of carbamazepine with oxcarbazepine

1 reference

12 December 2020

Oxcarbazepine final market image tablet formulation bioequivalence study after single administration and at steady state in healthy subjects

1 reference

12 December 2020

LC determination of oxcarbazepine and its active metabolite in human serum

1 reference

12 December 2020

Newer anticonvulsants: comparative review of drug interactions and adverse effects.

1 reference

12 December 2020

Carbamazepine and oxcarbazepine decrease phenytoin metabolism through inhibition of CYP2C19.

1 reference

12 December 2020

Pharmacokinetic variability of oxcarbazepine in epileptic patients

1 reference

12 December 2020

Oxcarbazepine. A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders

1 reference

12 December 2020

Pharmacokinetics of oxcarbazepine and carbamazepine in human placenta

1 reference

12 December 2020

Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics. A case report

1 reference

12 December 2020

Assessment of the bioequivalence of two oxcarbazepine oral suspensions versus a film-coated tablet in healthy subjects

1 reference

12 December 2020

Use of saliva for monitoring oxcarbazepine therapy in epileptic patients

1 reference

12 December 2020

Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures

1 reference

12 December 2020

Changes in unbound and total valproic acid concentrations after replacement of carbamazepine with oxcarbazepine

1 reference

12 December 2020

Recommendations on the clinical use of oxcarbazepine in the treatment of epilepsy: a consensus view

1 reference

12 December 2020

Effects of dextropropoxyphene on the steady-state kinetics of oxcarbazepine and its metabolites

1 reference

12 December 2020

Automated microanalysis of oxcarbazepine and its monohydroxy and transdiol metabolites in plasma by liquid chromatography

1 reference

12 December 2020

The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine

1 reference

12 December 2020

A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy

1 reference

12 December 2020

Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects

1 reference

12 December 2020

Therapeutic drug monitoring of the newer antiepileptic drugs

1 reference

12 December 2020

Effects of felbamate on the pharmacokinetics of the monohydroxy and dihydroxy metabolites of oxcarbazepine

1 reference

12 December 2020

A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients

1 reference

12 December 2020

Rectal absorption of oxcarbazepine

1 reference

12 December 2020

Disposition of the antiepileptic oxcarbazepine and its metabolites in healthy volunteers

1 reference

12 December 2020

Protein binding of oxcarbazepine and its primary active metabolite, 10-hydroxycarbazepine, in patients with trigeminal neuralgia

1 reference

12 December 2020

Oxcarbazepine: a review

1 reference

12 December 2020

Pharmacokinetics of 10-OH-carbazepine, the main metabolite of the antiepileptic oxcarbazepine, from serum and saliva concentrations

1 reference

12 December 2020

Substituting carbamazepine with oxcarbazepine increases citalopram levels. A report on two cases

1 reference

12 December 2020

Change in oxcarbazepine (Trileptal) formulation is associated with more side effects and higher blood concentrations

1 reference

12 December 2020

Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study

1 reference

12 December 2020

Determination of the R-(-) and S-(+) enantiomers of the monohydroxylated metabolite of oxcarbazepine in human plasma by enantioselective high-performance liquid chromatography

1 reference

12 December 2020

[Serum concentration of anticonvulsants. Practical guidelines for measuring and useful interpretation. Therapy Committee of the German Section of the International Epilepsy League]

1 reference

12 December 2020

Oxcarbazepine (GP 47.680): a possible alternative to carbamazepine?

1 reference

12 December 2020

Gas chromatographic/mass spectrometric assays for oxcarbazepine and its main metabolites, 10-hydroxy-carbazepine and carbazepine-10,11-trans-diol

1 reference

12 December 2020

Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects

1 reference

12 December 2020

Oxcarbazepine in the treatment of epilepsy

1 reference

12 December 2020

Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women

1 reference

12 December 2020

The influence of food on the disposition of the antiepileptic oxcarbazepine and its major metabolites in healthy volunteers.

1 reference

12 December 2020

Effects of the antidepressant drug viloxazine on oxcarbazepine and its hydroxylated metabolites in patients with epilepsy

1 reference

12 December 2020

Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy

1 reference

12 December 2020

Comparison of plasma and saliva concentrations of the active monohydroxy metabolite of oxcarbazepine in patients at steady state

1 reference

12 December 2020

Absence of interaction between oxcarbazepine and erythromycin

1 reference

12 December 2020

Therapeutic monitoring of the new antiepileptic drugs

1 reference

12 December 2020

10.2165/00003088-200342120-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

7 August 2017

0 references

1 reference